RYE, N.Y., March 21, 2011 /PRNewswire/ — Curemark, LLC,
(www.curemark.com), a drug
research and development company focused on the treatment of
neurological diseases, announced that the company has completed its
targeted enrollment of Phase III clinical trials for CM-AT, its autism
treatment.
Curemark has reached its targeted enrollment for the study of a
total 170 children, who are participating in the CM-AT Phase III
trial at 18 sites across the country.
“We have been extremely pleased with the enthusiastic response
of our clinical sites during the CM-AT Phase III trial process. We
now have the full complement of trial participants and will close
the trial to enrollment and begin the compilation process for FDA
submissions,” stated Dr. Bill Gannon, Curemark’s Medical
Director.
“This marks a significant milestone for us and our research
program,” said Dr. Joan Fallon, Curemark founder and CEO. “We are
grateful to our clinical sites for their participation.”
CM-AT targets enzyme deficiencies in autistic children.
These deficiencies affect the availability of amino acids,
the building blocks of chemicals that are essential for brain
function. Curemark’s autism therapy has received Fast Track
review status from the FDA.
About CUREMARK LLC
Curemark is a drug research and development company focused on
the treatment of neurological and other diseases, especially those
with dysautonomic components, by addressing certain key
gastrointestinal/pancreatic secretory deficiencies. The company’s
initial products are based upon breakthrough observations by its
founder, Dr. Joan Fallon, which revealed a lack of protein
digestion in children with autism and ADHD. To learn more about our
innovative science, visit www.curemark.com
Safe Harbor Statem
‘/>”/>
SOURCE
